Innovent receives approval from China’s NMPA for SINTBILO
17 Aug 2023
Drug ApprovalPhase 3AHA
Preview
Source: Pharmaceutical Technology
SINTBILO is approved in China to treat adult patients with primary hypercholesterolemia and mixed dyslipidemia. Credit: Naeblys / Shutterstock.com.
Innovent Biologics has secured approval from China’s National Medical Products Administration (NMPA) for SINTBILO (tafolecimab injection, anti-PCSK9 monoclonal antibody) to treat adult patients with primary hypercholesterolemia and mixed dyslipidemia.
SINTBILO can be used to treat primary hypercholesterolemia, including heterozygous familial and non-familial hypercholesterolemia.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsChina Contract Manufacturing Market Outlook - Trends, Ambitions, Key Players, Investment and Valu... GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - TRV-734 in Opium Withdrawal Syndrome GlobalData
View all
It is an lgG2 fully human monoclonal antibody which can attach to PCSK9 and reduce LDL-C levels by preventing PCSK9-mediated low-density lipoprotein receptor (LDLR) endocytosis.
Approved dosing regimens include 150mg Q2W, 450mg Q4W, and 600mg Q6W.
These regimens have been proven effective in lowering levels of LDL-C, total cholesterol (TC), non-high-density lipoprotein cholesterol (non-HDL-C), lipoprotein A (Lp(a)) and apolipoprotein B (ApoB).
Approval from the NMPA is based on results from Phase III CREDIT-1, CREDIT-2 and CREDIT-4 registrational studies.
Innovent clinical development vice-president Dr Lei Qian stated: “As the first PCSK9 antibody with proprietary intellectual property rights in China, the clinical development of tafolecimab condensed the efforts of many domestic experts and demonstrated the recognition from the regulatory authorities and the strength and capabilities of Innovent in the field of cardiovascular diseases.
“The approval of tafolecimab marks a meaningful milestone for Innovent’s strategic position in the cardiovascular and metabolism area.”
SINTBILO is the first drug from the company to enter the cardiovascular field.
Cardiovascular diseases are on the rise in China, with atherosclerotic cardiovascular disease responsible for over 40% of deaths among Chinese residents.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.